Cidara Therapeutics to Participate in November Investor Conferences
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) announced management will participate in November investor conferences in 2025.
Events: Guggenheim Healthcare Innovation Conference on Nov 11, 2025 at 8:00 AM ET (fireside chat) and Jefferies London Healthcare Conference on Nov 17, 2025 at 4:30 PM GMT (presentation). Live webcasts will be available in the Investors section of the company website and replays will be available for at least 30 days. Management will also hold one-on-one investor meetings during the conferences.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, CDTX gained 5.16%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $132M to the company's valuation, bringing the market cap to $2.69B at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.
Details are as follows:
Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 11, 2025
Time: 8:00 AM ET
Format: Fireside Chat
Event: Jefferies London Healthcare Conference
Date: November 17, 2025
Time: 4:30 PM GMT
Format: Presentation
The live webcast for the events can be accessed in the Investors section on the Company’s website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) present at the Guggenheim Healthcare Innovation Conference?
What time is Cidara Therapeutics (CDTX) presenting at the Jefferies London Healthcare Conference?
How can investors watch the Cidara (CDTX) conference webcasts?
How long will Cidara (CDTX) conference replays be available after the events?
Will Cidara Therapeutics (CDTX) meet with investors during the November conferences?
